Abstract: The invention relates to the use preferably of at least one active ingredient for the prophylaxis and/or therapy of a viral disease, wherein this active ingredient inhibits at least one component of the cellular signal transduction pathway for the activation of the transcription factor NF-kB such that the virus multiplication is inhibited. The present invention relates furthermore to the local, preferably aerogenic administration of the active ingredient according to the invention for inhibiting a virus multiplication. The active ingredient according to the invention may be combined with at least one further antivirally effective substance for the prophylaxis and/or therapy of a viral disease.

Abstract: A stationary inhalation apparatus for the individual controlled inhalation of therapeutic aerosols comprises a drug-release means 3, at least one drug reservoir 2, a reader 4 for reading out a patient's individual parameters and/or the aerosol parameters stored in a memory means and a control unit connected to the drug-release means 3 and the reader 4 for releasing the drug as a function of the read-out parameters. This stationary inhalation apparatus 1 permits the administration of different drugs to a multitude of patients.

Abstract: An inhalation device has a container 2 for an aerosol volume inhaled via a channel 15 and a mouthpiece 14, the container being located within a housing 12. The aerosol, in particular vitamin A, is introduced from a cartridge 17 into the interior of the container 2 via a nebulizer 18. The breath flow in the inhalation device is controlled via a control means 5 that keeps the inhalation flow essentially constant during the entire inhalation period.